793 reports of this reaction
3.4% of all DURVALUMAB reports
#4 most reported adverse reaction
RADIATION PNEUMONITIS is the #4 most commonly reported adverse reaction for DURVALUMAB, manufactured by AstraZeneca Pharmaceuticals LP. There are 793 FDA adverse event reports linking DURVALUMAB to RADIATION PNEUMONITIS. This represents approximately 3.4% of all 23,251 adverse event reports for this drug.
Patients taking DURVALUMAB who experience radiation pneumonitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
RADIATION PNEUMONITIS is moderately reported among DURVALUMAB users, representing a notable but not dominant share of adverse events.
In addition to radiation pneumonitis, the following adverse reactions have been reported for DURVALUMAB:
RADIATION PNEUMONITIS has been reported as an adverse event in 793 FDA reports for DURVALUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
RADIATION PNEUMONITIS accounts for approximately 3.4% of all adverse event reports for DURVALUMAB, making it a notable side effect.
If you experience radiation pneumonitis while taking DURVALUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.